The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Quantitative Biomarkers Could Be the Next Step for Precision Oncology
Just Enough Downstream Innovation
Downstream Operations Can Relieve the Pressure of Higher Titers and Cell Densities without Undue Disruption
Snag-Free Combing of the Proteome
With the Right Conditioning Raw Samples May Become More Manageable
Love, Science, and Autoimmune Therapy
NYU Professor Advances Autoimmune Disease Therapeutics
For full access to this article login to GEN Select now.
Systems Biology Alters Drug Development
Omics Tools Revitalize Field, but Deciphering High-throughput Data Is Still a Major Obstacle
- Research and development costs by pharmaceutical companies rose to an estimated $55.2 billion in 2006, with costs to develop a biologic drug reaching $1.2 billion. The potential of the Human Genome Project has yet to be fully realized, but many companies are starting to embrace systems biology as a ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.